- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04027764
Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer
July 18, 2019 updated by: Dai, Guanghai
Toripalimab Combined With S1 and Albumin Paclitaxel as First Line in Patients With Advanced Biliary Tract Cancer: a Single-arm,One Center, Phase II Clinical Study
The investigator's study is a single armed phrase II trial ,aiming to improve the effecacy of treatment for advanced billiary tract cancer by means of Toripalimab combining with S1 and Albumin Paclitaxel as first line in patients with advanced Biliary Tract Cancer.
treatment continually until disease progression or intolerable toxicity or Patients withdrawal of consent.and
target sample is 30+ patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Toripalimab: 240 mg , once every 2-3 weeks; S1: 80-120mg, bid; oral, day1-14; Albumin paclitaxel: 120mg/m2 , administered on the first day and the eighth day of each cycle; 21 days for a treatment cycle
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Recruiting
- Chinese PLA General Hospital
-
Principal Investigator:
- Guanghai Dai
-
Contact:
- Guanghai Dai
- Phone Number: 13801232381
- Email: daigh60@sohu.com
-
Contact:
- niansong qian
- Phone Number: 18201166535
- Email: 18701317301@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Patients with gallbladder and cholangiocarcinoma diagnosed by histology or cytology
- Liver function Child-Pugh grade A (5-6 points) or better grade B (≤ 7 points)
- ECOG score 0 or 1 point
- At least one measurable lesion
- no previous treatment
Exclusion Criteria:
- organs failure ,including liver ,heart ,kidney
- Have received a liver transplant in the past
- Active brain metastasis or spinal cord compression
- ECOG score 3 or 4 point
- Symptomatic peripheral neuropathy (CTCAE ≥ 2)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Toripalimab Combined With S1 and Albumin Paclitaxel
|
Toripalimab 240 mg ,every 2-3 weeks S1:80-120mg,bid;oral,d1-14; Albumin Paclitaxel:120mg/m2,D 1 \8
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective response rate
Time Frame: 1 year
|
ORR
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression free survival
Time Frame: 1 year
|
PFS
|
1 year
|
disease response rate
Time Frame: 1 year
|
DCR
|
1 year
|
overall survival
Time Frame: 1 year
|
OS
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2019
Primary Completion (Anticipated)
May 1, 2020
Study Completion (Anticipated)
May 1, 2021
Study Registration Dates
First Submitted
July 17, 2019
First Submitted That Met QC Criteria
July 18, 2019
First Posted (Actual)
July 22, 2019
Study Record Updates
Last Update Posted (Actual)
July 22, 2019
Last Update Submitted That Met QC Criteria
July 18, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TSA-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Biliary Tract Cancer
-
ASLAN PharmaceuticalsCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Biliary Tract CancerJapan
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerChina
-
Gyeongsang National University HospitalSamsung Medical Center; Dong-A University; Chung-Ang UniversityTerminatedMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerKorea, Republic of
-
Fudan UniversityRecruitingAdvanced Biliary Tract CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
University of Kansas Medical CenterRecruitingAdvanced Biliary Tract CancerUnited States
-
Peking Union Medical College HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Georgetown UniversityIpsenRecruitingAdvanced Biliary Tract CancerUnited States
-
Seoul National University HospitalBeiGeneActive, not recruitingAdvanced Biliary Tract CancerKorea, Republic of
-
Fudan UniversityRecruiting
Clinical Trials on Toripalimab Combined With S1 and Albumin Paclitaxel
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingResectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaChina
-
Peking University Cancer Hospital & InstituteRecruiting
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingRelapsed or Metastatic Non-small Cell Lung CancerChina
-
Guizhou Medical UniversityUnknown
-
Fourth Affiliated Hospital of Guangxi Medical UniversityRecruitingUterine Cervical Neoplasms | Adjuvant Chemotherapy | ChemoradiotherapyChina
-
Women's Hospital School Of Medicine Zhejiang UniversitySun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaboratorsRecruitingEpithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IVChina
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Fudan UniversityCompletedEsophageal Squamous Cell CarcinomaChina
-
China Medical University, ChinaRecruiting